Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2089–2112 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetes Mellitus, Chronic Kidney Disease, Diabetic Kidney Disease
Interventions: Cholecalciferol, Placebo; Dietary Supplement
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Type 1 Diabetes
Interventions: Etanercept, Vedolizumab; Drug
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: La Jolla, California • Seattle, Washington

Conditions: Diabetes Mellitus, Type 1
Interventions: Not listed
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prediabetes, Type 2 Diabetes, Obesity
Interventions: Intensive Lifestyle Intervention (ILI); Behavioral
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years to 65 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Breast Cancer, PreDiabetes, Type 2 Diabetes
Interventions: Nurse-practitioner led intervention; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 3
States / cities: Brooklyn, New York • Flushing, New York • New York, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release); Drug
Lead sponsor: Elcelyx Therapeutics, Inc.; Industry
Eligibility: 19 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Tempe, Arizona • Lincoln, Nebraska

Conditions: Work Related Stress
Interventions: Somatic Psychoeducational Intervention; Behavioral
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 1 Diabetes Mellitus, Multiple Sclerosis, Arthritis, Rheumatoid, Crohn's Disease, Psoriasis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 8 Years to 60 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 6
States / cities: New Haven, Connecticut • Atlanta, Georgia • Manhasset, New York + 3 more

Conditions: Diabetes, Pre-diabetes, Obesity
Interventions: Metformin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 10 Years to 79 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Volatile Organic Compounds, Hypoglycemia, Type 1 Diabetes Mellitus
Interventions: Collect exhaled breath during low and normal blood sugar; Diagnostic Test
Lead sponsor: East Tennessee State University; Other
Eligibility: 5 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Johnson City, Tennessee

Conditions: Cancer of Pancreas
Interventions: Bemcentinib, Nab-paclitaxel, Gemcitabine, Cisplatin; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Diabetes Mellitus, Type 1, Pregnancy in Diabetics, Pregnancy, High-Risk, Insulin Dependent Diabetes
Interventions: Hybrid closed loop insulin delivery system; Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 18 Years and older · Female only
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Aurora, Colorado • Tampa, Florida + 6 more

Conditions: Type 1 Diabetes
Interventions: Closed loop with sensor and Insulin, Closed loop with sensor, Insulin and Liraglutide; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Diabetic Complications
Interventions: Prontosan, Saline; Device
Lead sponsor: B. Braun Medical Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: San Diego, California • Chicago, Illinois

Conditions: Diabetes
Interventions: Managing Diabetes; Behavioral
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 11 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 2
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl); Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Walnut Creek, California • Saint Paul, Minnesota • Renton, Washington

Conditions: Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma
Interventions: FOLFIRINOX, Gemcitabine/nab-Paclitaxel, Radiation therapy, Capecitabine; Drug · Radiation
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pancreatic Carcinoma
Interventions: Botulinum Toxin Type A; Biological
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Pancreatic Cancer, Cancer of the Pancreas
Interventions: huCART-meso cells; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo, Victoza; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: California City, California

Conditions: Type I Diabetes Mellitus
Interventions: Glutamine, Placebo; Dietary Supplement
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 13 Years to 19 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Type 2 Diabetes
Interventions: CHICA Type 2 Diabetes Module; Other
Lead sponsor: Indiana University; Other
Eligibility: 10 Years to 18 Years
Enrollment: 1,369 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Type 1 Diabetes Mellitus, Diet Modification, Child, Only
Interventions: Low carbohydrate diet, Very low carbohydrate diet; Other
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 2 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Head and Neck Squamous Cell Carcinoma (HNSCC), Non-small Cell Lung Cancer (NSCLC), Esophageal Cancer, Gastric Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Breast Cancer, Ovarian Cancer, Cervical Cancer, Endometrial Cancer, Prostate Cancer, Urothelial Carcinoma, Neuroendocrine Tumor (NET), Neuroendocrine Carcinoma (NEC), Soft Tissue Sarcoma, Nuclear Protein in Testis (NUT) Carcinoma
Interventions: MT-4561; Drug
Lead sponsor: Tanabe Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Columbus, Ohio + 1 more

Search by objective public record fields.

Randomized Controlled Trial of Vitamin D3 in Diabetic Kidney Disease

Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D

Imaging Inflammation in Autoimmune Diabetes

Pathobiology and Reversibility of Prediabetes in a Biracial Cohort

Diabetes Care for Breast Cancer Patients

Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM

Potential Benefits of the Somatic Psychoeducational Intervention

T and B Cell Responses in Autoimmune Diseases

Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)

Biomarkers in Exhaled Breath of Glucose Fluctuation in Type 1 Diabetes

Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic Cancer

T1D Pregnancy & Me

Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting

Prontosan Versus Saline in the Cleansing of Chronic Leg Ulcers in Diabetic Patients

Diabetes Management Personal Trainer

Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula Following Distal Pancreatectomy

CAR T Cell Immunotherapy for Pancreatic Cancer

A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Glutamine and Insulin Sensitivity in Type I Diabetes

Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes

Safety of Low and Very Low Carbohydrate Diets in Young Children With Type 1 Diabetes

A Study of MT-4561 in Patients With Various Advanced Solid Tumors